Skip to main content
. 2015 Sep 18;9:1731–1740. doi: 10.2147/OPTH.S87972

Figure 1.

Figure 1

CASQ1 protein concentrations and CASQ1 antibody titer.

Notes: (A) Mean ± standard deviation, CASQ1 protein concentrations in thyroid tissues from patients having rs74123279 SNP with GH (61.56±18.32 pmol/mg), GO (81.44±43.98 pmol/mg) and as normal thyroid, from control patients with multinodular goiter or thyroid cancer (145.6±26.56 pmol/mg) determined from quantitative Western blotting. The difference between GH and controls and GO and controls was highly significant (Mann–Whitney test: *P=0.013 and *P=0.047, respectively). (B) Mean ± standard deviation, CASQ1 antibody titer in serum samples from patients having rs74123279 SNP that thyroid tissues were studied for measurement of CASQ1 protein concentrations with GH (305.1±45.65), GO (370.9±128.8), and as normal thyroid, from control patients with multinodular goiter or thyroid cancer (499.2±49.77) determined by enzyme-linked immunosorbent assay. The difference between GH and Controls was significant (Mann–Whitney test: *P=0.011), and GO and control failed to reach significance (Mann–Whitney test P=0.084).

Abbreviations: CASQ1, calsequestrin; SNP, single-nucleotide polymorphism; GH, Graves’ hyperthyroidism; GO, Graves’ ophthalmopathy; OD, optical density.